The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-04. Anything still debated is marked as such rather than presented as settled.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Clomipramine is the only TCA that has been shown to be effective in the treatment of OCD and that is approved by the FDA for the treatment of OCD; the other TCAs failed clinical trials for this indication, likely due to insufficient serotonergic activity.
== Medical use == Methaqualone's sedative-hypnotic properties were first identified in 1955. It gained popularity during the 1960s and 1970s for the treatment of insomnia, and as a general sedative and muscle relaxant. However, due to its abuse potential, it was eventually withdrawn from medical use. The drug was classified as pregnancy category D, meaning there was evidence of risk to the human fetus, and it was not recommended during pregnancy. Like other GABAergic substances, prolonged use of methaqualone can lead to drug tolerance, physical dependence, and withdrawal symptoms upon cessation.
==== Fraud conviction and imprisonment ==== The PTL Club's fundraising activities between 1984 and 1987 were reported by The Charlotte Observer, eventually leading to criminal charges against Bakker. Bakker and his PTL associates sold $1,000 "lifetime memberships", entitling buyers to an annual three-night stay at a luxury hotel at Heritage USA during that period. According to the prosecution at Bakker's fraud trial, tens of thousands of memberships were sold but only one 500-room hotel was ever finished. Bakker sold "exclusive partnerships" which exceeded capacity, raising more than twice the money needed to build the hotel. Much of the money paid Heritage USA's operating expenses, and Bakker kept $3.4 million. After a 16-month federal grand jury probe, Bakker was indicted in 1988 on eight counts of mail fraud, 15 counts of wire fraud and one count of conspiracy. In 1989, after a five-week trial which began on August 28 in Charlotte, North Carolina, a jury found him guilty on all 24 counts. Judge Robert Daniel Potter sentenced Bakker to 45 years in federal prison and imposed a $500,000 fine. At the Federal Medical Center, Rochester in Rochester, Minnesota, he shared a cell with activist Lyndon LaRouche and skydiver Roger Nelson. The United States Court of Appeals for the Fourth Circuit upheld Bakker's conviction on the fraud and conspiracy charges, voided Bakker's 45-year sentence and $500,000 fine and ordered a new sentencing hearing in February 1991.
First, the surfactant molecules adsorb between the surface layer and the subsurface layer. Second, the molecules exchange between the subsurface and the bulk solution. Third, the micelles relax, caused by the breaking of equilibrium between free molecules and micelles. The molecules making up each micelle are organized depending on the solution they are suspended in, with the more soluble portions in contact with the solution, and the less soluble portions of the molecule in contact with each other. Depending on the ratio of volume of the polar heads and nonpolar tail, various surfactants have been found to form larger aggregates, hollow, bi-layered structures known as vesicles. A notable surfactant that has been witnessed to form vesicles is AOT (Dioctyl sulfosuccinate sodium salt). These micelles and vesicles are relatively new discoveries; however, they have been utilized to transport agents within microfluidic systems, revealing future applications for microfluidic transports.
Light Source Spectra at the Wayback Machine (archived 2025-05-28) 60 W–100 W Incandescent light bulb spectra, from Cornell University Program of Computer Graphics Slow-motion video of an incandescent lightbulb filament Ribbon machine in operation at Osram-Sylvania in 2016
Sources: en.wikipedia.org
β-sheets are formed by H-bonds between an average of 5–10 consecutive amino acids in one portion of the chain with another 5–10 farther down the chain. The interacting regions may be adjacent, with a short loop in between, or far apart, with other structures in between. Every chain may run in the same direction to form a parallel sheet, or in the reverse direction to form an antiparallel sheet, or the chains may form a mixed sheet. The pattern of hydrogen bonding is different in the parallel and antiparallel configurations. Each amino acid in the interior strands of the sheet forms two H-bonds with neighboring amino acids, whereas each amino acid on the outside strands forms only one bond with an interior strand. Looking across the sheet at right angles to the strands, more distant strands are rotated slightly counterclockwise to form a left-handed twist. The Cα-atoms alternate above and below the sheet in a pleated structure, and the R side groups of the amino acids alternate above and below the pleats. The Φ and Ψ angles of the amino acids in sheets vary considerably in one region of the Ramachandran plot. It is more difficult to predict the location of β-sheets than of α-helices. The situation improves somewhat when the amino acid variation in multiple sequence alignments is taken into account.
In Euclidean geometry, a tangential quadrilateral (sometimes just tangent quadrilateral) or circumscribed quadrilateral is a convex quadrilateral whose sides all can be tangent to a single circle within the quadrilateral. This circle is called the incircle of the quadrilateral or its inscribed circle, its center is the incenter and its radius is called the inradius. Since these quadrilaterals can be drawn surrounding or circumscribing their incircles, they have also been called circumscribable quadrilaterals, circumscribing quadrilaterals, and circumscriptible quadrilaterals. Tangential quadrilaterals are a special case of tangential polygons. Other less frequently used names for this class of quadrilaterals are inscriptable quadrilateral, inscriptible quadrilateral, inscribable quadrilateral, circumcyclic quadrilateral, and co-cyclic quadrilateral. Due to the risk of confusion with a quadrilateral that has a circumcircle, which is called a cyclic quadrilateral or inscribed quadrilateral, it is preferable not to use any of the last five names. All triangles can have an incircle, but not all quadrilaterals do. An example of a quadrilateral that cannot be tangential is a non-square rectangle. The section characterizations below states what necessary and sufficient conditions a quadrilateral must satisfy to be able to have an incircle.
Neurotransmitter binds to the receptor The receptor undergoes a conformational change to allow G-protein complex binding GDP is exchanged with GTP upon G protein complex binding to the receptor The α-subunit of the G protein complex is bound to GTP and separates to bind with a target protein such as adenylate cyclase The binding to the target protein either increases or decreases the rate of second messenger (such as cyclic AMP) production GTPase hydrolyzes the α-subunit so that is bound to GDP and the α-subunit returns to the G protein complex inactive
=== Insulin === Insulin is given to reduce blood glucose concentration; however, as it also causes the movement of potassium into cells, serum potassium levels must be sufficiently high or dangerously low blood potassium levels may result. Once potassium levels have been verified to be greater than 3.3 mEq/L, then an insulin infusion of 0.1 units/kg/hr is started. The goal for resolution is a blood glucose of less than 200 mg/dL.
Sources: en.wikipedia.org
According to Rebecca Rocchi et al., 2024, creating natto by using Bacillus subtilis to ferment boiled red lentils, chickpeas, or green peas produced greater amounts of MK-7 than creating natto by using Bacillus subtilis to ferment boiled soybeans, lupins, or brown beans. Food frequency questionnaire-derived estimates of relative intakes of vitamins K in one northern European country suggest that for that population, about 90% of total vitamin K intakes are provided by K1, about 7.5% by MK-5 through MK-9 and about 2.5% by MK-4
A first-in-class medication is a prototype drug that uses a "new and unique mechanism of action" to treat a particular medical condition. While the Food and Drug Administration's Center for Drug Evaluation and Research tracks first-in-class medications and reports on them annually, first-in-class is not considered a regulatory category. Although many first-in-class medications qualify as breakthrough therapies, Regenerative Medicine Advanced Therapies or orphan drugs, first-in-class status itself has no regulatory effect.
The epidermis and dermis are separated by a thin sheet of fibers called the basement membrane, which is made through the action of both tissues. The basement membrane controls the traffic of the cells and molecules between the dermis and epidermis but also serves, through the binding of a variety of cytokines and growth factors, as a reservoir for their controlled release during physiological remodeling or repair processes.
General single cell studies including growth Cellular aging: microfluidic devices such as the "mother machine" allow tracking of thousands of individual cells for many generations until they die Microenvironmental control: ranging from mechanical environment to chemical environment Precise spatiotemporal concentration gradients by incorporating multiple chemical inputs to a single device Force measurements of adherent cells or confined chromosomes: objects trapped in a microfluidic device can be directly manipulated using optical tweezers or other force-generating methods Confining cells and exerting controlled forces by coupling with external force-generation methods such as Stokes flow, optical tweezer, or controlled deformation of the PDMS (Polydimethylsiloxane) device Electric field integration Plant on a chip and plant tissue culture Antibiotic resistance: microfluidic devices can be used as heterogeneous environments for microorganisms. In a heterogeneous environment, it is easier for a microorganism to evolve. This can be useful for testing the acceleration of evolution of a microorganism / for testing the development of antibiotic resistance. Viral fusion: these devices also allow the study of the several steps and conditions required for viruses to bind and enter host cells. Information regarding efficiency, kinetics and specific steps of the binding and fusion processes can be obtained using microfluidic flow cells.
== Discovery == Several of the components and reactions of the citric acid cycle were established in the 1930s by the research of Albert Szent-Györgyi, who received the Nobel Prize in Physiology or Medicine in 1937 specifically for his discoveries pertaining to fumaric acid, a component of the cycle. He made this discovery by studying pigeon breast muscle. Because this tissue maintains its oxidative capacity well after breaking down in the Latapie mincer and releasing in aqueous solutions, breast muscle of the pigeon was very well qualified for the study of oxidative reactions. The citric acid cycle itself was finally identified in 1937 by Hans Adolf Krebs and William Arthur Johnson while at the University of Sheffield, for which the former received the Nobel Prize for Physiology or Medicine in 1953, and for whom the cycle is sometimes named the "Krebs cycle". Independently citric acid cycle was identified in 1937 by German biochemists Carl Martius and Franz Knoop.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.